Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLYTE vs EUTHROID-0.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Replacement therapy in hypothyroidism (primary, secondary, tertiary),Suppression of TSH in thyroid cancer (off-label),Treatment of euthyroid goiter (off-label)
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal and hepatic function; clinically, steady-state is reached within 24-36 hours, and dosing interval adjustments may be needed in renal or hepatic impairment.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Levothyroxine (T4) is deiodinated to liothyronine (T3) primarily by type 1 and type 2 deiodinases in liver, kidney, and other tissues. T3 and T4 are also metabolized via glucuronidation and sulfation. Hepatic enzymes: UGT1A1, UGT1A3, SULT1A1.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Renal (approx. 20-40% as unchanged drug, primarily via glomerular filtration and tubular secretion); biliary/fecal (approx. 60-80% as metabolites and unchanged drug, with enterohepatic recirculation).
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Approximately 99% bound to serum proteins, primarily thyroxine-binding globulin (TBG), with lesser binding to transthyretin and albumin.
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Apparent volume of distribution is approximately 0.10-0.15 L/kg, indicating distribution primarily into extracellular fluid and highly protein-bound; small Vd reflects minimal tissue binding under steady-state conditions.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Oral bioavailability: 100% (tablets), as EUTHROID-0.5 is a combination product with synthetic T4 (levothyroxine) and T3 (liothyronine); T4 absorption is ~80% (fasting, taken with water), while T3 is nearly completely absorbed; overall bioavailability considered complete when taken as directed.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
No dose adjustment required for GFR >30 m L/min; for GFR <30 m L/min, consider reducing dose by 25-50% and monitor TSH.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50% and monitor TSH.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Oral: 0.5-1 grain (30-60 mg) per 70 kg body weight once daily; for children <70 kg, use 0.5 grains (30 mg) once daily adjusted to TSH levels.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Initiate at 0.5 grains (30 mg) orally once daily; titrate slowly with 0.5 grain increments every 4-6 weeks; monitor for tachyarrhythmias and osteoporosis.
None
No FDA boxed warning.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Cardiovascular effects: angina, arrhythmias, heart failure. Thyrotoxicosis: excessive doses may cause symptoms of hyperthyroidism. Bone mineral density reduction with long-term overreplacement. Adrenal insufficiency: may precipitate crisis in untreated patients. Diabetes: insulin/oral hypoglycemic requirements may increase. Myxedema coma: rapid correction can be fatal.
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Hypersensitivity to active ingredients or excipients. Untreated adrenal insufficiency. Thyrotoxicosis (hyperthyroidism). Acute myocardial infarction. Uncontrolled cardiovascular disease.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
Avoid taking with high-fiber foods, soy, or calcium supplements; separate by at least 4 hours.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoid, as untreated hypothyroidism is linked to congenital anomalies and neurodevelopmental deficits. No evidence of fetal harm from levothyroxine at therapeutic doses. Second and third trimester: transfers minimal amounts across placenta, but adequate maternal levels are essential for fetal neurodevelopment. Risk of fetal goiter if mother is overtreated (TSH suppression).
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
Levothyroxine is excreted into breast milk in minimal amounts, but no adverse effects in nursing infants have been reported. The milk-to-plasma (M/P) ratio is approximately 0.5 (range 0.4-0.6). Breastfeeding is considered safe while on levothyroxine therapy. Monitor infant thyroid function if high doses are used.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Pregnancy increases levothyroxine requirements in many women with hypothyroidism. Dose often increases by 30-50% starting at 4-6 weeks gestation. Monitor TSH and free T4 every 4-6 weeks and adjust dose accordingly to maintain euthyroid state. Postpartum, dose usually returns to prepregnancy levels.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Euthroid-0.5 contains liothyronine (T3). Monitor for signs of thyrotoxicosis due to rapid onset. T3 has a shorter half-life than levothyroxine; consider twice-daily dosing. Use with caution in elderly and patients with cardiac disease.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
Take exactly as prescribed, usually once daily.,Do not stop abruptly without consulting your doctor.,Report symptoms of hyperthyroidism: palpitations, tremor, anxiety, heat intolerance.,Store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLYTE vs EUTHROID-0.5, answered by our medical review team.
COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. EUTHROID-0.5 is a Thyroid Hormone Replacement that works by Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLYTE and EUTHROID-0.5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. The standard adult dose of EUTHROID-0.5 is: Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLYTE and EUTHROID-0.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. EUTHROID-0.5 is classified as Category C. EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.